Notably, emerging experimental evidence suggests that anti-TNF may also boost the efficacy of ICIs, as well as TKIs; therefore, their combined effect should be more extensively evaluated in preclinical models of NASH-associated HCC to guide their potential use in relevant clinical trials. Here, TNF is linked to hepatocellular carcinoma.